Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer

Jane Borley(Imperial College Healthcare NHS Trust), Sadaf Ghaem‐Maghami(Hammersmith Hospital), Angus McIndoe, J. Yazbek, Elizabeth Hird, Sarah P. Blagden(Churchill Hospital), Ian Carson, Alan Farthing(Imperial College London), Nishat Bharwani(Imperial College Healthcare NHS Trust), Charlotte S. Wilhelm-Benartzi(Cardiff University), R C N Williamson(Southmead Hospital), Victoria Stewart(Imperial College Healthcare NHS Trust)
BJOG An International Journal of Obstetrics & Gynaecology
August 5, 2014
10.1111/1471-0528.12992
Cited by 52

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
|eLife|2017|201
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
|Clinical Cancer Research|2011|168